SCHEMBL26811008

SCHEMBL26811008

CC1(C)CC(c2cc(Oc3ccccc3)nc(NS(=O)(=O)c3ccccc3)n2)CC(C)(C)C1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TSHR P16473 2/20 0.46
▸ SMN1; SMN2 Q16637 2/20 0.46
▸ PGR P06401 5/20 0.40
▸ KDM4E B2RXH2 2/20 0.39
▸ LMNA P02545 2/20 0.39
▸ HTT P42858 1/20 0.39
▸ GAA P10253 1/20 0.39
▸ PKM P14618 1/20 0.39
▸ ALDH1A1 P00352 2/20 0.38
▸ HPGD P15428 1/20 0.38
▸ HSD17B10 Q99714 1/20 0.38
▸ MAPT P10636 2/20 0.37
▸ CYP1A2 P05177 2/20 0.37
▸ CYP2C9 P11712 2/20 0.37
▸ CYP2C19 P33261 2/20 0.37
▸ NPSR1 Q6W5P4 2/20 0.37
▸ MEN1 O00255 1/20 0.37
▸ KMT2A Q03164 1/20 0.37
▸ ATM Q13315 1/20 0.37
▸ FFAR1 O14842 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29566782 0.87 TSHR (0.46) TSHRSMN1; SMN2PGRKDM4ELMNA
SCHEMBL24309955 0.87 TSHR (0.46) TSHRSMN1; SMN2PGRKDM4ELMNA
SCHEMBL26811032 0.85 TSHR (0.50) TSHRSMN1; SMN2PGRKDM4ELMNA
SCHEMBL26811003 0.83 TSHR (0.48) TSHRSMN1; SMN2PGRKDM4ELMNA
SCHEMBL26811034 0.82 TSHR (0.47) TSHRSMN1; SMN2PGRKDM4ELMNA
SCHEMBL29567034 0.81 TSHR (0.43) TSHRSMN1; SMN2PGRKDM4ELMNA
SCHEMBL24310011 0.81 TSHR (0.43) TSHRSMN1; SMN2PGRKDM4ELMNA
SCHEMBL26811036 0.81 TSHR (0.46) TSHRSMN1; SMN2PGRKDM4ELMNA
SCHEMBL26865625 0.81 TSHR (0.46) TSHRSMN1; SMN2PGRKDM4ELMNA
SCHEMBL26811002 0.80 TSHR (0.46) TSHRSMN1; SMN2PGRKDM4ELMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230373935-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR VERTEX PHARMACEUTICALS, SAN DIEGO 2023-11-23 — — US disclosed
US-20230373935-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR VERTEX PHARMACEUTICALS, SAN DIEGO 2023-11-23 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230373935-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR CFTR, SCNN1G, SCNN1B TSHR 1755/4885SMN1; SMN2 4847/4885PGR 4116/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback